NCT00863733View on ClinicalTrials.gov

Study of DMXAA (Now Known as ASA404) in Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

May 31, 1996

Primary Completion Date

March 31, 2000

Study Completion Date

March 31, 2000

Conditions

Solid Tumors

Interventions

DRUG

DMXAA

Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2

Sponsors

Lead Sponsor

Cancer Research UK

All Listed Sponsors

collaborator

Cancer Society Auckland

OTHER

lead

Cancer Research UK

OTHER

NCT00863733 - Study of DMXAA (Now Known as ASA404) in Solid Tumors | Biotech Hunter | Biotech Hunter